Light. Truth. Clarity.
Sanofi has announced its acquisition of vaccine manufacturer Dynavax for $2.2 billion. This strategic move comes as Sanofi seeks to bolster its portfolio following setbacks with some of its experimental drugs in clinical trials and regulatory processes.
This quick summary is automatically generated using AI based on reports from multiple news sources. The content has not been reviewed or verified by humans. For complete details, accuracy, and context, please refer to the original published articles.
